StemCell Therapy

BUZZ-Puma Biotechnology: Shares on the prowl:BUZZ-Puma Biotechnology: Shares on the prowl

** Puma Biotechnology shares soar 50.3 pct to $56.80 in heavy Monday morning trading; shares rise as high as $69.35, halted multiple times for volatility

** U.S. Food and Drug Administration posts documents reviewing Puma's neratinib for treating breast cancer ahead of FDA advisory committee meeting on the product on Weds

** Based on sensitivity analyses conducted, results appear to be generally similar to the primary analysis results, supporting an effect of neratinib, FDA staffers say in review documents

** Options market has been pricing in a move about 63 pct, positive or negative, in PBYI shares in reaction to neratinib review, JPMorgan analyst Cory Kasimov said in research note last week

** Short interest in PBYI shares stood at 21.5 pct of shares outstanding as of Apr 27, according to Thomson Reuters data

** Five analysts rate PBYI shares a "buy" or "strong buy", two rate "hold", according to TR data; median price target is $80

** PBYI shares have nearly doubled in 2017, against 9.7 pct rise for Nasdaq Biotechnology index

(This story has not been edited by timesofindia.com and is autogenerated from a syndicated feed we subscribe to.)

RELATED

Eos

AD BY AVANIR 2016 Avanir Pharmaceuticals, Inc, All Rights Reserved. Avanir is a trademark or Avanir Pharmaceuticals, Inc.

MSN

Read more:
Puma Biotechnology: Shares on the prowl - Times of India

WALTHAM, Mass.--(BUSINESS WIRE)--Bioverativ Inc. (NASDAQ: BIVV), a global biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, today announced that it has entered into a definitive agreement to acquire South San Francisco-based True North Therapeutics, a privately-held, clinical-stage rare disease biotechnology company, for an upfront payment of $400 million plus assumed cash. True North investors are also eligible to receive additional payments of up to $425 million contingent on the achievement of future development, regulatory and sales milestones.

As part of the acquisition, Bioverativ will obtain worldwide rights to True Norths lead candidate, TNT009, a first-in-class monoclonal antibody in development to treat cold agglutinin disease (CAD). CAD is a rare and chronic hemolytic condition that often leads to severe anemia, requiring numerous transfusions, and can result in life-threatening thrombotic events. There are no approved therapies for CAD, which occurs in approximately 16 people per million globally, including an estimated 5,000 people in the United States.

In May 2017, the U.S. Food and Drug Administration (FDA) granted TNT009 breakthrough therapy designation for the treatment of hemolysis in patients with primary CAD, and plans for the full clinical development program, including a registrational program, are underway. Breakthrough therapy designation was created by the FDA to expedite the development and review of medicines that target serious or life-threatening conditions and have shown preliminary evidence of potential clinical benefit.

One of our strategic priorities is to invest thoughtfully in business development with a focus on building our pipeline in areas where we believe we can make a real difference for patients, said John Cox, Chief Executive Officer of Bioverativ. This acquisition of True North is aligned with those goals and with our vision to become the leading rare disease company focused on blood disorders. It strengthens our pipeline with a potential first-in-class therapy to treat CAD, a rare blood disorder with a high unmet patient need.

People living with CAD currently have no approved treatment options and suffer with a significant disease burden including crippling fatigue, frequent transfusions and an increased risk of life-threatening thrombotic events such as pulmonary embolism and stroke, Mr. Cox continued. By combining True Norths industry-leading science in complement biology with Bioverativs expertise in hematology and robust clinical and commercial capabilities, we believe we can bring meaningful progress to CAD patients. In addition, this transaction is consistent with our capital allocation philosophy, and we expect it to create significant value for our shareholders over the long term."

Todays announcement and TNT009s breakthrough therapy designation are testaments to the innovative science underpinning our lead candidate and the strength of the True North team. We are delighted to have progressed our pipeline to this stage, said Nancy Stagliano, PhD, Chief Executive Officer of True North. Bioverativ is well positioned to advance the development and commercialization of TNT009 on behalf of CAD patients who are greatly in need of safe and effective treatments.

The FDA granted TNT009 breakthrough therapy designation based on data from a Phase 1b trial, which showed that TNT009 normalized hemoglobin levels in six of six study participants with primary CAD, increasing hemoglobin by an average of 4g/dL and resolving their anemia. All participants were transfusion free while on treatment. TNT009 was generally well tolerated. As of December 21, 2016, five of six participants (83.3%) with primary CAD experienced at least one adverse event; all were mild to moderate in severity and no adverse event was assessed as related to TNT009 by the investigator.

TNT009 is designed to selectively inhibit the classical complement pathway by targeting C1s and directly impacting the central mechanism of CAD. The only therapy in development that targets C1s, TNT009 has received orphan drug designation from the FDA and the European Medicines Agency. A number of other rare, complement-mediated diseases share the basic underlying pathological mechanism involving C1s that could potentially be addressed by TNT009.

True Norths second molecule, TNT020, is a discovery-stage, follow-on monoclonal antibody that targets activated C1s with the potential for less-frequent dosing and subcutaneous administration.

The acquisition will be financed through a combination of cash on hand and debt. It is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Act of 1976 in the United States, and is expected to close in mid-2017.

Conference Call and Webcast Bioverativ will hold a brief conference call and webcast today at 8:30 a.m. ET to discuss the transaction. The conference call can be accessed through the Investors section of Bioverativs homepage, investors.bioverativ.com, and an audio replay will subsequently be available on the website for at least one month.

About Cold Agglutinin Disease (CAD) CAD is a debilitating autoimmune hemolytic anemia in which autoantibodies target red blood cells, leading to red blood cell destruction via complement activation initiated by the C1 complex, causing chronic anemia, severe fatigue and potentially fatal thrombotic events. CAD occurs in approximately 16 people per million, affecting an estimated 5,000 people in the United States. Typically, symptom onset begins around age 60. There are currently no approved therapies for CAD. Treatment is aimed at normalizing hemoglobin levels through blood transfusions, steroids or off-label immunotoxic therapy; however, current treatment options are often intensive, incomplete or nondurable, leaving patients dependent upon frequent transfusions, which can lead to chronic iron overload.

About TNT009 TNT009 is a first-in-class, humanized, monoclonal antibody that is designed to selectively inhibit the classical complement pathway by targeting C1s, a serine protease within the C1-complex in the complement pathway of the immune system. With a unique mechanism of action and high target specificity, TNT009 is designed to selectively inhibit disease processes in the classical complement pathway while maintaining activity of the alternative complement pathway and lectin complement pathway, which are important for immune surveillance and other functions.

About True North Therapeutics True North Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class product candidates for complement-mediated diseases. The companys lead product candidate, TNT009, is designed to selectively inhibit a target in the classical complement pathway. True Norths antibody drug development is focused on the treatment of certain rare diseases mediated by the complement system. True North Therapeutics is located in South San Francisco, California. For more information, please visit http://www.truenorthrx.com.

About Bioverativ Bioverativ is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The companys mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit http://www.bioverativ.comor follow@bioverativ on Twitter.

Safe Harbor This press release contains forward-looking statements, including statements relating to: the completion of the transaction with True North and timing thereof; the expected benefits of the transaction, including the potential to bring meaningful progress to CAD patients and create shareholder value; and anticipated clinical trials and the timing thereof. These forward-looking statements may be accompanied by such words as anticipate, believe, could, estimate, expect, forecast, intend, may, plan, potential, project, target, will and other words and terms of similar meaning. You should not place undue reliance on these statements.

These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: risks that the transaction will be completed in a timely manner or at all; risks of failure to satisfy the conditions precedent to completion of the transaction, including the ability to secure regulatory approvals in a timely manner or at all; uncertainty of whether Bioverativ can achieve the expected benefits from the transaction and successfully integrate the operations of True North; risks of unexpected costs, liabilities or delays; integration difficulties, including the ability to retain key personnel; risks that Bioverativ will be able to obtain financing on satisfactory terms, if at all; risks relating to the protection of intellectual property; risks and uncertainties relating to product development, clinical trials, regulatory process and approvals, and commercialization that may impact or alter Bioverativs anticipated business plans, strategies and objectives; and other risks and uncertainties described in the Risk Factors section of Bioverativ's quarterly and annual filings with the Securities and Exchange Commission.

These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Here is the original post:
Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics - Business Wire (press release)

Sanofi Genzyme's Kendall Square site.

Federal regulators Monday OKd a drug made by Cambridge-based Sanofi Genzyme to treat rheumatoid arthritis, a painful condition that affects millions of people worldwide, including more than 1.3 million in the United States.

The regulatory sign-off on Kevzara, co-developed with Regeneron Pharmaceuticals Inc. of Tarrytown, NY, marked the second major US drug approval this year for Sanofi Genzyme, the specialty care arm of French drug giant Sanofi SA. In late March, the Food and Drug Administration gave a green light to the companys medicine to treat severe forms of eczema.

Advertisement

The FDA approved Kevzara for adult patients with moderately to severely active rheumatoid arthritis who have not responded adequately to other treatments. Doctors can prescribe Kevzara as a sole treatment or in combination with other medicines. The drugs label will include a safety notice that it can cause side effects, including serious infections, in some patients.

We have very high hopes for Kevzara, said Jonathan Sadeh, a Sanofi vice president and clinical research lead for the drug program. It fills an important unmet need. In tests of the experimental drug on rheumatoid arthritis patients, he said, weve shown a clinically meaningful impact on symptoms and on slowing down the progression of the disease.

Get Talking Points in your inbox:

An afternoon recap of the days most important business news, delivered weekdays.

Mondays approval came seven months after the FDA delayed a decision on the rheumatoid arthritis treatment, citing deficiencies found during inspection of a Sanofi manufacturing site in Normandy, France. The problems have since been addressed.

The drug was approved by Canadian regulators in January, and Sanofi Genzyme and Regeneron which will split the revenues are awaiting decisions in Europe and Japan by the end of the year.

Unlike the eczema drug Dupixent, which biopharma analysts have pegged as a blockbuster product with peak sales topping $1 billion a year, Kevzara will enter a market crowded with existing medicines that work in different ways. The top-selling rheumatoid arthritis treatment is Humira, sold by North Chicago, Ill., biopharma AbbVie Inc.

Advertisement

But the global rheumatoid arthritis market has been estimated at $20 billion, and its been growing at about 2 percent a year. That means Kevzara could generate significant revenue if it can make inroads into the market.

In more than a half dozen late-stage clinical trials, Kevzara outperformed Humira in improving the condition of patients who didnt respond well to a common first-line treatment called methotrexate. Its important to give clinicians more options in treating this disease, Sadeh said. If you have an inadequate response to one mechanism, its better to go to another mechanism.

Kevzara is a type of biologic drug known as a monoclonal antibody. It works by blocking the activation of cell receptors that cause inflammation of joints throughout the body. Sadeh said the same type of action could potentially treat many other diseases.

Scientists at Sanofi Genzyme and Regeneron, who are collaborating in a broad drug development alliance, are actively reviewing other indications, Sadeh said.

In addition to Kevzara, the collaboration already has yielded two other approved drugs. One is Dupixent; the other is Praulent, which treats hypercholesterolemia, a condition that affects people with extremely high levels of cholesterol.

Go here to see the original:
FDA approves Sanofi Genzyme rheumatoid arthritis drug - The Boston Globe

Prevention.com

This Is What Rheumatoid Arthritis Actually Feels Like Prevention.com Most people think arthritis only affects those hovering around retirement age. But rheumatoid arthritis, a chronic inflammatory disorder, can actually strike those in their 20s or 30s. And unlike some other rheumatic diseases, the side effects of the ...

More:
This Is What Rheumatoid Arthritis Actually Feels Like - Prevention.com

BY RYAN STEWART For The Oklahoman Published: May 23, 2017 5:00 AM CDT Updated: May 23, 2017 5:00 AM CDT

Phlebotomist Lisa Fulks prepares to draw blood from a donor on the Oklahoma Blood Institute mobile blood drive unit parked on Robinson in downtown Oklahoma Cityin 2015. [Photo by Doug Hoke, The Oklahoman Archives]

The Oklahoma Medical Research Foundation and the Oklahoma Blood Institute have joined forces to combat rheumatoid arthritis.

The institutes will utilize OBI's new software system, Bio-Linked, to match willing blood donors with researchers at OMRF to build a volunteer group for StopRA, an innovative U.S.-based prevention trial for rheumatoid arthritis, which is funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, through its Autoimmunity Centers of Excellence program.

Rheumatoid arthritis, or RA, is a chronic illness characterized by inflammation of the lining of the joints. The symptoms include pain, swelling and stiffness in the joints, and ultimately the disease can result in loss of function and disability. While little is known about how RA develops, studies show some people at risk for the disease can be identified through testing for an autoantibody called anti-CCP.'

We know that individuals with this protein in their blood are at a higher risk, said Dr. Judith James, StopRA investigator and OMRF's vice president of clinical affairs and chair of the foundation's Arthritis and Clinical Immunology Research Program. But we didn't know how we could screen a large number of healthy individuals to see if they're walking around with this risk factor to address the disease before it develops. That led to this beautiful partnership with OBI.

OBI's Bio-Linked initiative has made this early screening possible. Unveiled in late 2016, Bio-Linked is a unique software system in which OBI's generous blood donors are matched with medical research projects like StopRA.

This was created because we know there is a great need for people who are willing to participate in research, said Charles Mooney, OBI vice president of quality management and new business ventures. Our blood donors are the perfect people to recruit to do research because they are responsive, they care and they are willing to step up to do what needs to be done.

How it works

This partnership allows blood donors to sign up to have some of their extra serum submitted as blinded or de-identified samples to be tested for specific antibodies associated with RA. If they test positive for the CCP antibody, OMRF will contact OBI, who will reach out to the donors with more information about the study.

In the first 6 weeks of the new arrangement between OBI and OMRF, more than 3,000 people agreed to have their blood tested for the anti-CCP antibody. Out of that group, about 40 people had the risk factor and were contacted by OBI. Nearly all of them subsequently contacted OMRF to inquire about the trial.

James said the goal of the trial is to assess whether early treatment can prevent these individuals from ever becoming RA patients.

Coming off the promising initial response, OMRF and OBI are working to secure funding for another round of screening.

It is enormously rewarding for the Oklahoma Blood Institute to partner with Dr. James and OMRF in their valuable rheumatoid arthritis research, said Dr. John Armitage, OBI president and CEO.

Our donors have always been amazingly generous in giving blood to care for patients, but through this study, they are helping find ways to prevent disease symptoms from ever appearing in people with risk factors. This is a perfect public health collaboration whereby our healthy and willing volunteers are matched with brilliant scientists looking for people to help them unlock new medical treatments.

If you are interested in participating in StopRA or would like more information, please call 271-7221 or email Virginia-roberts@omrf.org. For more information on OBI's Bio-Linked initiative, go to Bio-Linked.org.

Preventing this disease from taking off would be life-changing not only for the individuals, but also their friends and families, said Dr. Stephen Prescott, OMRF president. This powerful partnership positions us to do something about it.

Ryan Stewart is media relations coordinator for Oklahoma Medical Research Foundation.

Continued here:
OMRF, OBI partner to fight rheumatoid arthritis - NewsOK.com

INVER GROVE HEIGHTS, Minn. (KMSP) - A new nationwide stem cell study is hoping to give dogs with arthritis a better life. Minnesota is one of about a dozen states involved in this ground breaking clinical trial.

Fourteen-year-old Max has arthritis and his owner, Lynsey Rossi says, "When he walks sometimes he can't keep balance and he doesn't have the stability." Rossi is excited Max was selected to participate in this new double blind stem cell study, even though she doesn't know if Max was injected with the placebo or the stem cells.

Dr. Ann Valenti at the Inver Grove Heights Animal Hospital is tracking dozens of dogs' progress.

"They're taking the stem cells from the umbilical cords of puppies that would typically be waste material and they're purifying it and making it into a product that has a very rich stem cell component to it," Valentisaid.

The hope is the stem cells will produce more cartilage and joint fluid.

Max gets a lameness test every few months for up to six months to test his ability to walk and jog.

The good news for all dogs in this cutting edge trial, in the end, every single one will get injected with stemcells.

If you'd like to know if your dog could participate there are several qualifications, such as the dog has to be older than a year. Also it has to be in general good health besides arthritis.

Owners have to keep a diary about their dog plus they receive $400 in compensation for participating.

You can find out if your dog would qualify and learn more by going to dogstemcellstudy.com

Original post:
Study aims to give dogs with arthritis greater comfort in old age - KMSP-TV

Steroid injections don't do a lot to help relieve the pain of arthritis in the knees, a new study has found, suggesting the common treatment may be not be helpful.

The study found that giving patients cortisone injections every three months was no better than giving them a placebo injection for alleviating their knee pain in patients from osteoarthritis.

In fact, the researchers found that the steroid injections actually contributed to a loss in bone cartilage over two years.

Osteoarthritis is the most common type of arthritis, affecting more than three million Canadians. The condition is marked by the breakdown in joints of cartilage, which is the tough elastic material that protects the ends of bones.

When the underlying bones begin to rub together, it results in pain and stiffness. It can also lead to synovitis, which is an inflammation of the membrane that lines the joints.

There is no cure for the condition, but doctors sometimes inject corticosteroids directly into the knee joint in a bid to quickly reduce some of the inflammation.

Some doctors are reticent to offer the treatment since it's known that repeated injections can actually contribute to the breakdown of cartilage in the knee.

For the study, a team led by Dr. Timothy E. McAlindon, of Tufts Medical Center in Boston randomly assigned 140 patients with knee osteoarthritis and synovitis to injections of either a corticosteroid called triamcinolone, or a simple saline solution, every 12 weeks for two years.

Id hoped that we might see some benefit from the triamcinolone because it supresses inflammation and we know there is inflammation in the knee joints, McAlindon said.

The researchers found that those receiving the injections of triamcinolone saw significantly greater cartilage volume loss than the saline group saw.

And though both groups experienced some relief from pain, there wasn't a significant difference between the two groups. Physical function remained about the same in both groups as well.

"The results of this study do not support the use of long-term, repeated corticosteroid injections for the management of pain or structural progression in osteoarthritis, and in fact indicate that there may be more cartilage loss in people who receive steroids," McAlindon said.

The study appears in the Journal of the American Medical Association.

Dr. Bheeshma Ravi, an orthopaedic surgeon at Sunnybrook Health Sciences Centre in Toronto, says the study confirms what a lot of surgeons have known for some time.

This study will really help doctors and patients understand these injections -- especially steroid injections -- dont really have much of an impact on patient pain and should not really be part of the care, he told CTV News.

Ravi believes that many steroid injections are "patient-driven," meaning it's patients who are requesting them because they have exhausted other pain management options but are leery of having joint replacement surgery.

"A lot of doctors use these injections in lieu of counselling patients that they may benefit from surgery," Ravi said

But the injections rarely work to relieve pain and only serve to delay joint replacement surgery, which has been shown to relieve pain and increase mobility.

"Sometimes people delay surgery for too long -- and sometimes they do that by using these injections and various other injections offered -- they may get to a stage where their function is so low, that the surgery can't really make much of a difference (to their ability to function)."

With a report by CTV News medical specialist Avis Favaro and producer Elizabeth St. Philip

Read more:
Study questions steroid injections for knee arthritis - CTV News

When a joint develops osteoarthritis, some of the cartilage covering the ends of the bones gradually roughens and becomes thin, and the bone underneath thickens.

According to Arthritis Research UK, over eight million people in the UK suffer from osteoarthritis - a condition perceived as only a disorder that affects the elderly.

However, now experts have revealed body fat can help treat bone joint conditions, including osteoarthritis.

A new device gently suctions, processes and uses a patient's own fat tissue to provide a potential source of stem cells and growth factors to promote healing.

Experts said it could help people who cant easily move their joints.

GETTY

Fat has long been used for support of tissue repair and replacement

Orthopedic physicians at a US medial centre are the first sports medicine specialists in the area to offer treatment with the device, called Lipogems, used at the time of arthroscopic surgery.

The FDA - the food and drug administration in the US approved Lipogems for use in November 2016.

"The technology is ideal for patients with certain orthopedic conditions, such as painful joints - including the knee, ankle or shoulder - with limited range of motion, said Dr Brian Cole, professor of orthopedic surgery and section head of the Rush Cartilage Restoration Center at Rush University Medical Centre.

Additionally, it can be used in soft tissue defects located in tendons, ligaments, and/or muscles to improve the biologic environment," he said.

"Fat has long been used for support of tissue repair and replacement.

"Fat has the ability to be a source of important cells which produce important proteins involved with healing and reduction in inflammation."

GETTY

Getty

1 of 12

During the process, fat cells are taken from the abdomen or thigh while the patient is sedated with a local anaesthetic.

The Lipogem procedure rinses and cleans inflammatory oils and blood from the harvested fat and keeps the beneficial properties of the fat tissue, which is injected into the injured site.

The entire procedure from harvesting to the injection is completed in less than 30 minutes.

The fat tissue tends to remain in the area where it is injected instead of being immediately reabsorbed by the body, allowing the body to maximise the benefits of the injection for an extended period of time.

GETTY

Following injection, the tissue promotes healing and symptom reduction as early as three weeks after treatment.

The treatment can be used when standard options - such as steroid injections or non-steroidal anti-inflammatory drugs dont provide enough relief.

It offers benefits for people who are unable to get surgery, would like an alternative to surgery, or it can be used in conjunction with their surgery, Dr Cole said.

We are excited to be offering this alternative to our patients and are conducting ongoing basic science and clinical research trials on patients with knee arthritis and other conditions to investigate the role of stem cells and growth factors that are present in the small blood vessels in fat.

Visit link:
Arthritis cure on horizon - THIS unusual treatment can ease symptoms - Express.co.uk

The global market for rheumatoid-arthritis drugs is expected to top $19 billion by 2020. Three of the 10 best-selling drugs in the world are arthritis medications. Pharmaceutical companies that market arthritis medications are making a lot of money -- and, as a result, some rank among the top dividend stocks around.

AbbVie (NYSE:ABBV), Pfizer (NYSE:PFE), and Johnson & Johnson (NYSE:JNJ) appear to be the best dividend stocks among arthritis drugmakers. Here's why.

Image source: Getty Images.

AbbVie's Humira is the world's best-selling rheumatoid-arthritis drug and best-selling prescription drug overall, raking in $16 billion in sales last year. Thanks in large part to the success of Humira, AbbVie's dividend currently yields 3.84%, one of the highest among biopharmaceutical companies.

What's even better is that AbbVie has raised its dividend 60% since being spun off from parent Abbott Labs in 2013. The company appears to be in excellent position to continue dividend increases in the future, with a dividend payout ratio of less than 61% and growing earnings.

AbbVie depends on Humira for 63% of its total revenue, but the biotech has another rising star in cancer drug Imbruvica. In addition, AbbVie's pipeline includes several potential blockbusters, with cancer drug Rova-T and autoimmune-disease drugs ABT-494 and risankizumab at the top of the list.

Some might worry about threats from biosimilars to Humira. Amgen (NASDAQ:AMGN) won U.S. regulatory approval for its Humira biosimilar last year. However, AbbVie thinks it will be able to fend off U.S. rivals through 2022 by defending its array of patents for Humira.

Pfizer markets Enbrel along with partner Amgen. The drug ranked as the No. 2 rheumatoid arthritis drug in sales and the No. 3 prescription drug overall. Pfizer's portion of revenue generated by Enbrel in 2016 totaled $2.9 billion. (Amgen made nearly $6 billion from the drug.)

Enbrel was one of four megablockbuster drugs in Pfizer's product lineup last year. These big moneymakers helped Pfizer pay out a very attractive dividend, which currently yields 3.88%.

Although Pfizer's growth has been sluggish in recent years, the company should be in good shape for better performance in the future. Pfizer could become one of the biggest success stories in the cancer drug market, with soaring sales for Ibrance, the addition of Xtandi with its acquisition of Medivation last year, and a promising new drug, Bavencio.

Pfizer also should generate nice growth outside the oncology arena. Atopic dermatitis drug Eucrisa could reach peak annual sales of around $2 billion. Sales are also growing strongly for anticoagulant Eliquis, which Pfizer co-markets with Bristol-Myers Squibb.

Johnson & Johnson's Remicade stood as the world's third highest-selling arthritis drug last year. It also held the spot as the No. 5 prescription drug in overall sales. However, the position for Remicade could be in jeopardy in the near future as Pfizer cranks up its efforts in marketing its biosimilar, Inflectra.

J&J's dividend yield currently stands at 2.65%. That's lower than a few arthritis-drug stocks that aren't on this list, notably including both Amgen and Bristol-Myers Squibb (which markets Orencia). So why did J&J leapfrog these other stocks?

It comes down to history. Johnson & Johnson boasts one of the most stellar track records of any dividend stock. The company has increased its dividend for 54 consecutive years. That track record gives J&J a distinct advantage in attracting dividend-seeking investors.

The company's reliable cash flow should allow Johnson & Johnson to keep its streak of dividend increases going for a long time to come. J&J also has what I consider to be among the strongest pipelines of any major drugmaker. The company has 30 late-stage clinical programs and will add even more once its acquisition of Actelion closes.

Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

See the original post here:
The 3 Best Dividend Stocks in Arthritis Medication -- The Motley Fool - Motley Fool

Ablynx said today it will receive a 15 million ($16.9 million) milestone payment from Merck KGaA after the pharma giant approved its preclinical package for ALX-1141, setting the stage for advancing the osteoarthritis candidate into clinical studies.

Merck KGaA will oversee clinical development of ALX-1141, Ablynx said.

ALX-1141 is the first candidate to be developed through a 6-year-old collaboration between the companies. Ablynx and Merck KGaA agreed in 2011 to develop candidates against two Merck-selected osteoarthritis targets, with Merck at the time agreeing to pay Ablynx 20 million ($22.5 million) upfront.

Ablynx is eligible for approximately 120 million ($135 million) in development, regulatory, and commercial milestones, plus tiered royalties into double digits, upon successful development and approval of ALX-1141.

ALX-1141 and the second osteoarthritis candidate are being developed using Ablynxs platform based on single-domain antibody fragments, or Nanobodies, that contain the unique structural and functional properties of naturally occurring heavy-chain-only antibodies. According to Ablynx, the platform is designed to allow for rapid generation and large-scale production of novel biological therapeutics that have potential in a wide range of human diseases.

Obtaining preclinical proof-of-concept was an important milestone in this collaboration, Ablynx CEO Edwin Moses, Ph.D., said in a statement. With no disease-modifying drugs currently approved for osteoarthritis, there is a huge unmet need for new treatments. This Nanobody has the potential to become a first-in-class treatment option for patients suffering from this degenerative joint disease.

Dr. Moses added that ALX-1141 is the second Nanobody expected to enter clinical development from any of four collaborations between Ablynx and Merck KGaA. The other is a bispecific anti-interleukin (IL)-17A/F (M1095) Nanobodydesigned to neutralize the proinflammatory cytokines IL-17A and IL-17Fwhich showed positive results as a psoriasis treatment in a Phase Ib study, the companies said in January.

In February, Ablynx included among its significant clinical and regulatory catalysts anticipated for 2017 the potential advancement to the clinic of another Nanobodya cancer candidate co-developed with Merck & Co. under a 5.78 billion ($6.5 billion) immuno-oncology collaboration launched in 2014 and expanded the following year.

See the original post here:
Ablynx Wins 15M from Merck KGaA as Arthritis Candidate Nears Clinic - Genetic Engineering & Biotechnology News

Question: How can a blood test determine if I have prediabetes? How much weight do I need to lose to bring my numbers down?

Answer: Doctors typically perform one of three blood tests to diagnose prediabetes, a condition marked by blood sugar (glucose) levels that are higher than normal but not high enough to qualify as diabetes. While prediabetes often leads to full-fledged Type 2 diabetes, many people can hold the condition in check if they lose a relatively small amount of weight and increase their physical activity, said Dr. Rhonda Bentley-Lewis, an assistant professor of medicine at Harvard Medical School.

I stress to my patients that were not talking about a huge amount of weight. Just 5 to 7 percent of ones body weight she said. Thats 10 to 14 pounds for someone who weighs 200 pounds.

Two of the tests require fasting, which helps prevent results being distorted by a prior meal and provides an even baseline, Bentley-Lewis said.

One, the fasting plasma glucose test, checks blood glucose levels after an 8 to 10 hour fast; results of 100 to 125 milligrams per deciliter indicate prediabetes. The other, the oral glucose tolerance test, is the most sensitive. It checks blood glucose levels after fasting and then two hours after you consume a sweetened drink; levels of 140 to 199 after the drink indicate prediabetes.

A third test, the A1C test, may be the most convenient because it doesnt require fasting. It measures your average blood glucose levels over the past two to three months; results of 5.7 percent to 6.4 percent, which indicate the percentage of red blood cells that have glucose attached to them, indicate prediabetes.

Though doctors often repeat a test to confirm a diabetes diagnosis, they do not always do so for a prediabetes diagnosis, Bentley-Lewis said.

Doctors can treat prediabetes with medication, but many patients prefer to try weight loss and exercise first, she said.

Among thousands of people with prediabetes who participated in a national study called the Diabetes Prevention Program, those who received counseling about lifestyle changes, like losing a modest amount of weight, stepping up physical activity and reducing the amount of fat and calories in their diets, were able to reduce their risk of developing diabetes by 58 percent.

Roni Caryn Rabin writes for The New York Times.

Go here to read the rest:
How much weight should you shed to avoid diabetes? - The San Diego Union-Tribune

LIHUE Malia Bever is no stranger to Type 1 diabetes.

The Koloa teen was 4 years old when she was diagnosed, after her mom noticed Malias eating patterns and weight had changed.

During the next few years, there were ups and downs as the family adjusted to her diagnosis and navigated the questions that came with it.

Theres this sort of angry stage people go through after theyre diagnosed, and that happened with me when I was younger, Bever said. Ive experienced every stage of it, up to now.

The Southern California native is now 17. She moved to Kauai with her family in 2014. She was involved in Type 1 diabetes-centered youth outreach programs in California, and shes still using her time in Hawaii to find ways to connect people who have been diagnosed.

In 2016, Bever started a support group for people with Type 1 diabetes on Kauai, focused on connecting teens and tweens. She held a summer bash that year, and is repeating the Type 1 Kauai Family Retreat at Makanalani Estates in Kilauea June 9-11. It is free.

The retreat is about being together with people like you, Bever said. We share our stories and we have some information about Type 1 diabetes, because for the longest time I didnt even really know what it was.

One story Bever shares is getting a service dog when she was 9 as a way to help manage the emotional swings and changes in her body.

Everything got a little easier when we got Nick Jonas thats his name, Bever said. He used to go everywhere with me, but now he stays home quite a bit.

She said its important for kids with the diagnosis to know about tricks to live well with Type 1 diabetes, like getting a service animal.

In 2010, Bever attended Camp Sweeney in Texas. Thats where she got the inspiration for the Kauai retreat, which is her own smaller-scale version.

The Texas camp convenes each year for three weeks. Its a traditional summer camp with games, arts and crafts, and a paddle out, all for kids with Type 1 diabetes. But it also has medical staff and trained dietitians, so kids can focus on fun.

Its such an epic camp, Bever said.

For the Kauai retreat, Bever is including everyone in the family.

Bevers mom, Jessica, and grandmother, Diana, will be lending a hand with the event, and will share how they coped with Malias diagnosis as shes grown up.

My mom let me go to sleepovers and stuff, Bever said. A lot of kids with Type 1 dont get to do that kind of stuff because of the insulin, but she let me be more free.

In addition to Makanalanis open space with donkeys, sheep and horses, Bever plans to set up a slip-n-slide and have an evening where adults and kids can play separately.

Last year, we had a movie night downstairs and a nice dinner for the adults upstairs, Bever said. Were going to do something like that this year, too.

Info: email type1kauai@ yahoo.com or call 278-8765.

Read the original:
Type 1 diabetes group throws bash - Thegardenisland.com

With Promising Potential

No matter how modern the world has become, there are certain ailments that continue to persist. One of these is diabetes, and according to the World Health Organization (WHO), there are now over 422 million people in the world suffering from it. Generally characterized as a problem in blood sugar levels, diabetes has two variants an insulin-dependent one, known as type 1 diabetes (T1D), and type 2 diabetes thats non-insulin-dependent.

In the United States, the Juvenile Diabetes Research Foundation reports that about 1.25 million people have T1D. The cause of this particular diabetes variant still remains unknown, and treatments generally involve pumping insulin daily into the patients body. As such, theres still no known cure for T1D. However, researchers from the University of Miami Leonard M. Miller School of Medicine in Florida may have just made it possible to develop one.

In a study published in the New England Journal of Medicine, the researchers described how clinical trials involving pancreatic islet cell implants to the omentum the tissue covering organs in the abdomen shows promise in treating T1D. Islet transplantation can restore euglycemia and eliminate severe hypoglycemia in patients with [T1D], the researchers wrote. The omentum has a dense vascularized surface for islet implantation, drains into the portal system, and is easily accessible.

Pancreatic islets are endocrine cell clusters found throughout the organ, which is normally involved with insulin and glucagon production in healthy individuals. The researchers found that using donor islets combined with a T1D patients own blood plasma makes for effective islet implants into the omentum. This works better than previous attempts to implant islets in the liver, which could cause inflammation. The omentum then becomes sort of a mini-pancreas that could produce insulin for T1D patients. The results thus far have shown that the omentum appears to be a viable site for islet implantation using this new platform technique, lead author David Baidal told Endgadget.

The patients involved in the clinical trials were weaned off from their usual dose of insulin 17 days after the transplant. Their glucose levels subsequently showed improvements. At 12 months, in response to a 5-hour mixed-meal tolerance test, the 90-minute glucose level was 266 mg per deciliter (14.6 mmol per liter); this level decreased to 130 mg per deciliter (7.1 mmol per liter) at 300 minutes, according to the study.

While this isnt the only research out there that tries to solve the problem of diabetes, its certainly the first thats given patients a steady supply of insulin from inside their bodies, setting them free from their insulin injections. Similar studies have also been conducted to remove the dependence of type 2 diabetes patients from their usual medicines.

It would still take some time, however, before the actual feasibility of this treatment is determined. Data from our study and long-term follow up of additional omental islet transplants will determine the safety and feasibility of this strategy of islet transplantation, but we are quite excited about what we are seeing now, Baidal said.

Read more:
A New Clinical Trial Just Made Diabetes Patients Insulin Independent - Futurism

Tragic Tommy Green died in his sleep. (Picture by Facebook)

People from across the the world are dabbing for a 21-year-old Bury St Edmunds student who died in his sleep last week.

Kind-hearted type 1 diabetes sufferer Tommy Green went to sleep with a stomach bug but unexpectedly fell into severe hypoglycemia, which is extremely low blood sugar levels, during the night.

The Nottingham Trent University student did not wake up from his sleep.

Friendsurged people to dab, a dance craze which started in America, toboost awareness of the potentially fatal condition and to raise money for charities searching for a cure.

Type 1 diabetes, which is distinct form type 2, is believed to affect more than 400,000 people in the UK.

A friend of the student said: At the weekend, one of our type 1 heroes was lost.

Tommy was a kind-hearted university student who was sleeping off a simple tummy bug but sadly never woke up, a fear for so many in the type 1 community and sadly a reality for this family.

Type 1 families will come together, candles will be lit, prayers will be said and T1 families will be dabbing in memory of Tommy.

His mother Jo Green, who lives in Dubai, said: Thank you all so much you are all completely amazing. We are staggered by your wonderful support. We are lifted to think this is raising awareness for diabetes.

Hundreds of people have posted photos of themselves doing the now-famous dab move using the hashtag #dab4tommy.

Tommys friend Russell Edge posted: Tom was my very best friend the kindest soul. We miss him every day.

MORE: Ouch! Its 10 years since Charlie bit his brother

MORE: Tolkiens great-grandson completes bucket list set by his dying brother

Originally posted here:
Tragic student who died in his sleep inspires 'dabbing for Diabetes' - Metro

MELBOURNE, AUSTRALIA--(Marketwired - May 19, 2017) - Propanc Biopharma Inc.(OTCQB: PPCH) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that fresh new insights have emerged into how cancer stem cells (CSCs) are able to resist standard treatments, become more aggressive and spread rapidly. Published in Oncogene, by researchers from the Bellvitge Biomedical Research Institute south of Barcelona, Spain, the findings have significant implications for Propanc Biopharma's lead product PRP, which reprograms CSCs so that they are no longer malignant and a threat to the patient. PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.

One of the authors from the study, Dr Miguel ngel Pujana, describes why tumors adapt to and resist certain therapies, like mTOR inhibitors, a treatment used in advanced stages of breast cancer. He links mTOR inhibition with increased expression of certain genes, like EVI1, which contributes to epithelial to mesenchymal transition (EMT), a key process by which cancer cells become stem cell-like, motile and invasive, seeding new tumors. Dr Miguel concludes, "Tumor cells are able to adapt to treatment through a phenotype (character) shift that makes them more aggressive and sustains their metastatic potential." Data from hundreds of cell lines expand on the concept that CSCs are frequently the source of therapy resistance and metastasis, the main cause of patient death from cancer.

"When administering PRP to a patient, we are essentially reprogramming CSC gene expression, pushing these cells back to a normal, less malignant state, so they die naturally," said Dr Kenyon, Propanc's Chief Scientific Officer. "Reversing the EMT process is a key feature of PRP and is fast becoming a credible solution to controlling CSCs, which are responsible for cancer spreading, or metastasis, the main cause of patient death from cancer."

"The latest scientific discoveries regarding CSC reprograming shows we are on the right track, which we believe is not reflected in our current market capitalization," said James Nathanielsz Propanc's Chief Executive Officer. "Nevertheless, we are advancing towards First-In-Human studies and remain excited about developing PRP as a new therapeutic approach for cancer sufferers. We remain focused on delivering long term value to our loyal shareholders."

The rationale for developing PRP is based on a set of in-vitro studies on CSCs, as well as xenograft and syngeneic mouse models of ovarian and pancreatic cancers, respectively. In summary, these data indicate that the dramatic reduction of cellular markers associated with the process of EMT as a consequence of PRP treatment, could not only reverse the EMT process with the implication to stop tumor progression and metastasis, but also seem to suppress the development of CSCs. Consequently, these results are strong indicators of the therapeutic potential of PRP that could be categorized as an anti-CSC therapeutic drug.

Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 Billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing a combined market segment of $14 Billion predicted in 2020, by GBI Research.

To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video

To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.

About Propanc Biopharma:Propanc Biopharma is a clinical stage biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: http://www.propanc.com.

Forward-Looking Statements:All statements other than statements of historical fact contained herein are "forward-looking statements" for purposes of federal and state securities laws. Forward-looking statements may include the words "may," "will," "estimate," "intend," "continue," "believe," "expect," "plan" or "anticipate" and other similar words. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties including those regarding our earnings, revenues and financial condition, our ability to implement our plans, strategies and objectives for future operations, our ability to execute on proposed new products, services or development thereof, our ability to establish and maintain the proprietary nature of our technology through the patent process, our ability to license from others patents and patent applications, if necessary, to develop certain products, our ability to implement our long range business plan for various applications of our technology, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, the results of our clinical research and development, competition in the industry in which we operate, overall market conditions, and any statements or assumptions underlying any of the foregoing. Other risks, uncertainties and factors that could cause actual results to differ materially from those projected may be described from time to time in reports we file with the Securities and Exchange Commission, including our reports on Forms 10-K, 10-Q and 8-K. We do not intend, and undertake no obligation, to update any forward-looking statement contained herein, except as required by law.

View post:
Propanc Biopharma Highlights PRP's Potential to Reprogram Cancer Stem Cells (CSCs) - Markets Insider

Cradled in his fathers arms, overcome with tears streaming down his cheeks, Jeff Belge had two questions:

Am I going to lose my eye? Will I ever play baseball again?

Belge, 9 years old at the time, and his cousin were skipping stones when he accidentally was hit squarely in the right eye with a rock that had slipped from his cousins hand, shattering his cornea. His eye became deflated like a balloon, white puss oozing out of it.

Fast forward seven years later, Belge is at a hotel in Atlanta, rough-housing with teammates after a long day of summer league baseball games. One of the Syracuse natives teammates accidentally sticks his finger in the same right eye, undoing the two surgeries from the first incident, and rupturing the globe in his eye. It had become deflated again.

You have to prepare yourself that we may have to remove his eye, his mother Karen was told by one doctor.

Yet, here he is, two traumatic experiences later, still pitching, an integral part of one of the best baseball teams in St. Johns history, a 6-foot-5 southpaw who throws mid-90s heat and has a professional future.

Belge is legally blind in his right eye, which was saved. The freshman can only see some colors and outlines of objects, relying solely on the left eye, in which he has 20/25 vision. But he doesnt see it as a limitation. It has been that way since he was 9. Its who he is.

I find ways around it, said Belge, who wears protective glasses. It doesnt really bother me.

Its just me having a dream and just following it. Its a bump along the way I had to get over.

After the first incident, doctors couldnt tell him if baseball was going to be part of his future. He had to miss a month of school. He didnt bother asking after the first few times. He didnt need anyone to answer the question for him.

I just told myself I was going to play, Belge said. I got on the field as soon as I could.

He started the road back with his little league coach, who would hit him tennis balls in the outfield, so he could get used to using just the one eye without fear of hurting himself. Belge would spend hours with his dad at the local park, pitching and hitting, training himself like he was learning the sport from scratch. When he got back into games, nearly a year later, he didnt think about the eye.

His focus was that intense. The injury had given him big-time motivation, determination, to push through things, he said.

If anything was a challenge, his father Tom said, it was trying to slow him down.

Belge made the Henninger High School varsity as a seventh grader, was also a standout basketball player and played quarterback for a season. He made it onto major league scouts radar as a sophomore, after striking out 11 opposite Scott Blewett, a second-round pick in 2014.

Belge was nearly a top draft pick despite the second incident costing him most of the summer prior to his senior year of high school, depriving him of several notable showcases in front of scouts.

The Red Sox, Brewers and Royals all offered Belge significant money in the third round, according to his father, money they turned down. Still, the Red Sox drafted him in the 32nd round as a courtesy.

I certainly hope in two years hes a Red Sox, said Ray Fagnant, the Red Sox area scout who followed him in high school. Hes a kid you always root for. Nothing is ever going to scare him.

The family liked the idea of him attending St. Johns, believing the experience of living in New York City and continuing to develop was too good to pass up. That bond with the Queens school grew in the summer before his senior year, following the incident. Depressed he was going to miss the showcases and unable to do much of anything baseball-related for six weeks, Belge sunk into depression. He was being forced to relive the traumatic accident from his childhood. All the work he had put in, all the time he spent staring down adversity, felt like a waste.

It put me in a bad place mentally, he said.

Pitching coach Corey Muscara, his lead recruiter, made sure to stay in close contact with Belge. Muscara would call him almost daily and suggest goals making his bed, losing a pound of weight per week, finishing a book as a way for him to keep active. It wasnt forgotten when it came time to make a decision about his future. It set it in stone, Wow, this guy really has my best interest at heart, Belge recalled.

Though Belge said he isnt thrilled with his performance this year on the mound hes 3-3 with a 5.13 ERA in nine starts the southpaw has been an integral part to one of the best teams in program history, just three wins shy of the most in St. Johns history. He has been a weekend starter as a freshman for the nationally-ranked Red Storm, with freshman Nick Mondak missing almost the entire year due to arm trouble and Kevin Magee just returning from his own injury.

I dont know how he does it, Mondak said of his teammate pitching with vision in only one eye. Its amazing.

Belge doesnt see it that way. This always has been his goal: to play baseball at a high level, and one day reach the major leagues.

The two accidents didnt change that. He expects a lot of himself, and remains confident he can be a major factor for St. Johns (40-9) in next weeks Big East Tournament and the NCAA Tournament that follows. He already has overcome so much, a few poor outings wont do much to that belief.

He doesnt take anything for granted, Karen said. When you have setbacks and have things taken from you, a lot of kids wouldve crumbled. A lot of kids wouldnt say I can do this again, maybe be scared of the mound, be afraid to get hurt. Not Jeffrey.

Its made Jeffrey a much stronger-willed person. It wasnt going to own him, and it didnt.

See the article here:
'Am I going to lose my eye?': St. John's star overcomes blindness - New York Post

Sankara Eye Foundation (SEF)s Dallas Chapter organized their inaugural walkathon, a 5K Fun Run/Walk for Vision on May 13 at Myers Park and Event Center in McKinney.

The event brought over 1,200 registered participants including Mayor-Elect George Fuller and his wife, Maylee-Thomas Fuller.

The event included a variety of entertainment for people of all ages bounce houses, pony rides, slides, fun filled music by local radio host DJ Moody, food and beverage choices via food trucks and even a fast-beat, choreographed flash mob led by Sweta Rajesh.

Close to $30,000 was raised with sponsorships from a host of local businesses including diamond sponsors Saravanaa Bhavan and Texas Institute for Neurological disorders.

A campaign to Open 300 Eyes was the highlight of the event. With a $30 donation, a donor gifts vision to a blind person in one of the many SEF eye hospitals in India. The assembled crowd surpassed the target by donating funds to open 450 eyes, aided by Fuller, who pledged to open 50 eyes. Baylor Scott & White Medical Center, Centennial, based in Frisco, matched the contribution toward the first 100 eyes. Participants who pledged received an I opened an eye sticker.

Established in the Bay Area, SEF is a nonprofit organization that has been working for the past 12 years with the goal of eradicating curable blindness in India. SEF has currently established nine community hospitals as well as two city hospitals and will soon embark on two new hospital projects.

SEF provides free eye care for those unable to afford it, those members of the rural poor, and this accounts for 80 percent which is approximately 150,000 people per year of the surgeries performed at their hospitals. For information visit giftofvision.org.

View post:
SEF Dallas raises close to $30000 toward eradicating curable blindness in India - Star Local Media

As of late, the Street has taken a bit closer look at shares of Prana Biotechnology Limited (NASDAQ:PRAN). In the latest session the stock moved-6.63%, putting the stock value at$2.24.

Most investors are likely looking for that next stock that is ready to take off running. Maybe the focus is on finding a stock that has recently taken a turn for the worse for no real apparent reason. As we all know, as quickly as a stock can drop in price, it can bounce back just as fast.

Although the popular stocks that receive a high level of media coverage tend to recover quicker after a sell-off, there may be plenty of under the radar stocks that are ripe for buying. Scoping out these potential market gems may help repair a portfolio that has taken a hit for any number of reasons.

Is Prana Biotechnology Limited Ready to Move higher? Sign Up For Breaking Alerts on this Stock Before the Crowd.

The average investor might not have the time to monitor every single tick of a given stock, but taking a look at historical performance may help provide some valuable insight on where the stock may be trending in the future. Over the past week, Prana Biotechnology Limited (NASDAQ:PRAN) has performed 0.90%. For the past month, shares are -20.85%. Over the last quarter, shares have performed -3.03%. Looking back further, Prana Biotechnology Limited stock has been -23.29% over the last six months, and 37.42% since the start of the calendar year. For the past full year, shares are -38.63%.

There is rarely any substitute for diligent research, especially when it pertains to the equity markets. No matter what strategy an investor employs, keeping abreast of current market happenings is of the utmost importance. Everyone wants to see their stock picks soar, but the stark reality is that during a market wide sell-off, this may not be the case. Recently, shares of Prana Biotechnology Limited (NASDAQ:PRAN)have been seen trading -27.98% away from the 200-day moving average and -14.63% off the 50-day moving average. The stock is currently trading -66.52% away from the 52-week high and separated 47.37% from the 52-week low. Prana Biotechnology Limiteds RSI is presently sitting at 40.44.

New investors may sometimes be working with limited capital. Choosing which stocks to own can be a tough decision. Individuals may be deciding on whether to buy 10 shares of a stock trading at $100 as opposed to purchasing 100 shares of a stock trading at $10. We have recently been focusing on stocks that are trading under the $10 price level. We are constantly monitoring technical and fundamental factors that may lead to breakouts for these relatively cheap (in terms of price) stocks.

See the original post here:
Looking For a Catalyst: Update on Prana Biotechnology Limited (NASDAQ:PRAN) - Morgan Research

Photo: Courtesy Of Laurie Gaboardi

Bryce Lewis of New Milford was proud to be this years youth honoree of the 2017 Danbury Walk to Cure Arthritis.

Bryce Lewis of New Milford was proud to be this years youth honoree of the 2017 Danbury Walk to Cure Arthritis.

Lewis raises funds for Arthritis Walk

Spirits were high at the April 30 Danbury Walk to Cure Arthritis.

Numerous residents of the greater New Milford area attended the event, which featured New Milford youth Bryce Lewis as the walks youth honoree.

Bryce, 11, was diagnosed with juvenile idiopathic arthritis at age 5 at Connecticut Childrens Medical Center, after waking one morning and not being able to move.

Bryces team, Bryces Battle Droids named after one of his favorite movies, Star Wars raised just over $4,000.

The national walked raised $5,896,059.

The local walk included a three-mile and one-mile course, activities for the entire family and stories shared by local honorees.

In addition to raising funds for the walk, Bryce raised funds by presenting a screening of Star Wars last month, and donated books about juvenile arthritis to the library and local elementary schools.

Joining Bryce as an honoree were adult honoree Barbara Duffin, of New Fairfield, who has lived with rheumatoid arthritis for over 10 years, and medical honoree Dr. Richard Roseff, of Danbury, a rheumatologist.

See the original post here:
Lewis raises funds for Arthritis Walk - The Greater New Milford Spectrum

RICHMOND, Va. (WRIC) Communities in the Richmond area rallied together Saturday for the 2017 Walk to Cure Arthritis.

That was held at VCUs Neuroscience Orthopedic and Wellness Center.

Arthritis is the leading cause of disability in the United States today.

Saturdays walk raised money to find a cure for the condition.

We want everyone to know that arthritis is not just an old persons disease, Laura Boon, the Executive Director of the Arthritis Foundation said. It affects children of all ages, adults of all ages and it can be debilitating for some people. Its unacceptable. Its not a normal part of the aging process and we want to raise awareness so people know that.

To find out more and to fight and walk to cure arthritis, check out the Arthritis Foundations website.

Donations will be accepted through August 31.

Never miss another Facebook post from 8News

Find 8News onTwitter,Facebook, andInstagram; send your news tips toiReport8@wric.com.

View original post here:
Communities rally together for the 2017 Walk to Cure Arthritis - WRIC